Comparison

Exenatide vs. Maridebart Cafraglutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Exenatide

Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Exenatide	Maridebart Cafraglutide
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Exenatide

Full entry →

Maridebart Cafraglutide

Full entry →

Frequently asked questions

What is the difference between Exenatide and Maridebart Cafraglutide?: Exenatide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Exenatide or Maridebart Cafraglutide?: The highest available evidence level is "Human RCT" for Exenatide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Exenatide and Maridebart Cafraglutide in Germany and the United States?: Germany: Exenatide — Prescription, Maridebart Cafraglutide — Unapproved. United States: Exenatide — Prescription, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Exenatide

Maridebart Cafraglutide

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Exenatide and Maridebart Cafraglutide?

Exenatide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Exenatide or Maridebart Cafraglutide?

The highest available evidence level is "Human RCT" for Exenatide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Exenatide and Maridebart Cafraglutide in Germany and the United States?

Germany: Exenatide — Prescription, Maridebart Cafraglutide — Unapproved. United States: Exenatide — Prescription, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.